期刊文献+

CD40突变体融合蛋白真核表达载体的构建及表达

Construction of eukaryotic expression vector of muCD40-IgG1Fc fusion protein and its expression in CHO cells
下载PDF
导出
摘要 目的:构建CD40突变体(muCD40)融合蛋白的真核表达载体pIRES2-EGFP/muCD40Ig,并在中国仓鼠卵巢细胞(CHO)中表达,以获得muCD40Ig融合蛋白,为检测体内可溶性muCD40分子建立实验基础。方法:从L929/muCD40基因转染细胞中通过RT-PCR扩增出人muCD40胞外段基因序列,从人脾脏细胞中扩增出人IgG1恒定区基因,分别插入真核表达载体pIRES2-EGFP,采用Superfectin转染CHO细胞,G418筛选出能稳定分泌muCD40Ig蛋白的基因转染细胞并亚克隆。筛选出的阳性克隆经无血清培养后,收集上清进行Western blot检测;并收集细胞进行RT-PCR鉴定,同时用流式细胞仪分析muCD40Ig蛋白与CD40L的结合能力。结果:成功构建了人pIRES2-EGFP/muCD40Ig重组真核表达载体,PCR及Western blot结果显示该CHO基因转染细胞能够稳定分泌人muCD40Ig蛋白;流式检测muCD40Ig融合蛋白能够与CD40L分子结合。结论:获得了能稳定分泌人muCD40Ig的CHO基因转染细胞株,muCD40Ig融合蛋白具有与CD40L结合的能力。 AIM: To construct an eukaryotic expression vector of human muCD401g fusion protein, and to express it stably in Chinese hamster ovary (CHO) cells for obtaining muCEM01g fusion protein and founding an experimental basis for investigating the soluble muCEM0 molecule in vivo. METHODS: Extracellular domain of human muCD40 gene was amplified by RT-PCR from L929/muCD40-transfected cells, and the genes encoding the constant regions of human IgG1 were cloned from human splenocytes. The genes were inserted into eukaryotic expression vector plRES2-EGFP, respectively. The recombinant vector was transfected into CHO cells by Superfectin. The transfected cells stably secreting muCD401g fusion protein was selected with G418 and subcloned. The serum-free culture supernatant of the selected positive clone was subjected to Western blotting and RT-PCR to confirm the expression of the fusion gene. The affinity of muCD401g and L929/CD40L was analyzed by flow cytometry (FCM). RESULTS: The eukaryotic expression vector plRES2-EGFP/muCD401g was constructed successfully. PCR and Western blotting showed that the transfected CHO cell strain was able to secret muCD401g fusion protein stably. FCM demonstrated a good affinity between muCD401g and L929/CD40L. CONCLUSION: A transfected CHO cell strain stably expressing muCD401g fusion protein has been obtained, and the muCD401g fusion protein can bind to CD40L.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2012年第7期673-676,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金青年项目(81101556) "重大新药创制"科技重大专项(2009ZX09103-704) 江苏省普通高校研究生科研创新计划项目(CXZZ11_0110) 苏州市科技发展计划(SYSD2011084)
关键词 CD40突变体 融合蛋白 真核表达 CD40 mutant fusion protein eukaryotic expression
  • 相关文献

参考文献15

  • 1Davies CC, Mason J, Wakelam MJ, et al. Inhibition of phosphatidy linositol 3-kinase-and ERKMAPK-regulated protein synthesis reveals the pro-apoptotic properties of CIM0 ligation in carcinoma cells [ J ]. Biol Chem, 2004, 279(2) : 1010 - 1019.
  • 2Jiang Q, Weiss JM, Back T, et al.. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CIM0antibody in cancer treatment [ J ]. Cancer Res, 2011, 71 ( 12 ) : 4074 - 4084.
  • 3Fransen MF, Sluijter M, Morrean H, et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody[ J]. Clin Cancer Res, 2011, 17(8) : 2270 -2280.
  • 4eRater J, Antonia SJ, Burris HA, et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors[J]. Cancer Biol Ther, 2010, 10 (10) : 983 -993.
  • 5Li R, Chen WC, Wang WP, et al. CIM0 signaling activated by ago- nistic anti-CIM0 monoclonal antibody 5Cll has different effects on biological behavior of gastric carcinoma cells [ J ]. Immunol Lett, 2010, 131(2): 120-125.
  • 6Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab ( SGN-40; humanized anti-CIM0 monoclonal antibody) in patients with multiple myeloma [ J]. Haematologica, 2010, 95(5) : 845 -848.
  • 7Chiodoni C, Iezzi M, Guiducci C, et al. Triggering CD40 on endothe- lial cells contributes to tumor growth [ J ]. J Exp Med, 2006, 203 (11) : 2441 -2450.
  • 8Howard LM, Miller SD. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease [ J ]. Autoimmunity, 2004, 37 (5) : 411 - 418.
  • 9Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CIMO-CIMOL co-stimulation blockade[ J]. Transplantation, 2005, 80 (4) : 546 -554.
  • 10Buchner K, Henn V, Grafe M, et al. CD40 ligand is selectively expressed on CD4 + T cells and platelets: implications for CD40- CD40L signaling in atherosclerosis[ J]. J Pathal, 2003, 201 (2) : 288 - 295.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部